<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">KdWvnKQFfJ4SP7Xt78ZFRQm</article-id>
      <article-id pub-id-type="other">00001</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2021000100001</article-id>
      <article-id pub-id-type="publisher-id">abc.20201098</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20201098</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>O Astronauta e a Jabuticaba</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-8769-1411</contrib-id>
          <name>
            <surname>d&#8217;Avila</surname>
            <given-names>Andre</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Melo</surname>
            <given-names>Marco F. Vidal</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgname">Hospital SOS Cardio</institution>
        <addr-line>
          <named-content content-type="city">Florian&#243;polis</named-content>
          <named-content content-type="state">SC</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Hospital SOS Cardio, Florian&#243;polis, SC - Brasil</institution>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution content-type="orgdiv1">Department of Anesthesia, Critical Care and Pain Medicine</institution>
        <institution content-type="orgname">Massachusetts General Hospital</institution>
        <addr-line>
          <named-content content-type="city">Boston</named-content>
          <named-content content-type="state">Massachusetts</named-content>
        </addr-line>
        <country country="US">EUA</country>
        <institution content-type="original">Harvard Medical - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts &#8211; EUA</institution>
      </aff>
      <author-notes>
        <corresp id="c01"> Correspond&#234;ncia: Andre d&#8217;Avila &#8226; Hospital SOS Cardio - 401.121. CEP 88030-000, Florian&#243;polis, SC &#8211; Brasil E-mail: <email>andredavila@mac.com</email>
				</corresp>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>03</day>
        <month>02</month>
        <year>2021</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <month>01</month>
        <year>2021</year>
      </pub-date>
      <volume>116</volume>
      <issue>1</issue>
      <fpage>1</fpage>
      <lpage>3</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <kwd>Pandemia/preven&#231;&#227;o e controle</kwd>
        <kwd>Dexametasona</kwd>
        <kwd>Anti-Inflamat&#243;rios, Hidroxicloroquina</kwd>
        <kwd>COVID-19</kwd>
        <kwd>SARS-CoV-2</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="8"/>
        <page-count count="3"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>A cada 2 anos, a partir de milhares de inscri&#231;&#245;es de todo o mundo, cerca de 100 pessoas, n&#250;mero semelhante ao de vagas anuais em muitas escolas m&#233;dicas, s&#227;o encaminhadas a NASA para uma serie de entrevistas, exames m&#233;dicos, f&#237;sicos e psicol&#243;gicos. Assim como nas faculdades de medicina, o processo para selecionar astronautas &#233; muito competitivo e tenta identificar os candidatos mais aptos &#224;s miss&#245;es espaciais. O Conselho de Sele&#231;&#227;o procura por pessoas excepcionais dada a complexidade das tarefas a serem excetuadas e apenas 0,1% dos aspirantes a astronauta s&#227;o selecionados. Tal como acontece com alunos de medicina, alguns candidatos cancelam sua inscri&#231;&#227;o ap&#243;s familiarizar-se com a tremenda carga de trabalho e perigos envolvidos em tornar-se um astronauta. Candidatos a m&#233;dico e astronauta t&#234;m muito em comum: precisam ser pessoas motivadas, com enorme capacidade de concentra&#231;&#227;o, fi&#233;is ao m&#233;todo e ao treinamento exaustivo e capazes de compreender que equ&#237;vocos em suas condutas podem ter consequ&#234;ncias catastr&#243;ficas.</p>
    <p>Aos olhos dos pacientes, m&#233;dicos ser&#227;o sempre pessoas excepcionais tais como os astronautas. Quanto mais complexo o problema, melhor treinado e preparado o paciente espera que seu m&#233;dico seja para poder lidar com aquela situa&#231;&#227;o. Assim como na NASA, pacientes esperam que o m&#233;dico por eles selecionados tenham sido excepcionalmente bem preparados e que possam tomar as melhores decis&#245;es pertinentes as suas vidas de maneira pragm&#225;tica, informada e pronta. No lan&#231;amento do &#244;nibus espacial, mesmo sabendo que tudo pode dar errado, n&#227;o d&#225; tempo de fazer figa nem torcer para que tudo d&#234; certo: ou o astronauta est&#225; preparado ou n&#227;o entra no foguete. Da mesma forma, a decis&#227;o do m&#233;dico n&#227;o pode se basear em cren&#231;a ou esperan&#231;a de que vai dar certo.</p>
    <p>Diferentes tipos de pacientes optam por diferentes perfis de m&#233;dico, mas todos, invariavelmente, buscam algu&#233;m que possa abordar o problema de acordo com condutas bem estabelecidas e predefinidas durante o treinamento e pela experi&#234;ncia do profissional. Nossos pacientes, e isso j&#225; foi estudado, preferem que seu destino dependa mais da t&#233;cnica do que da sorte e indulg&#234;ncia. Entretanto, o controle de qualidade dos processos de forma&#231;&#227;o do astronauta e do m&#233;dico s&#227;o muito diferentes. Nos primeiros, um grupo pequeno, o controle &#233; mais f&#225;cil de ser exercido e os equ&#237;vocos corrigidos com mais rapidez e objetividade. No caso dos m&#233;dicos n&#227;o. Menos durante na faculdade, mas principalmente depois de completado o treinamento formal, a qualidade e os resultados da forma&#231;&#227;o ficam mais dif&#237;ceis de ser avaliados. Os extremos s&#227;o de reconhecimento relativamente simples: hospitais e profissionais de excel&#234;ncia <italic>versus</italic> imper&#237;cia ou neglig&#234;ncia flagrantes. Mas existe uma enorme lacuna entre esses dois pontos onde, na verdade, a grande maioria dos atos m&#233;dicos acontecem e o controle &#233; mais complicado de ser exercido.</p>
    <p>Isso ficou patente na pandemia.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup> Entre o uso de oz&#244;nio por via retal - seria engra&#231;ado se n&#227;o fosse tr&#225;gico - e os estudos randomizados mostrando a inefic&#225;cia de varias interven&#231;&#245;es, in&#250;meros m&#233;dicos e institui&#231;&#245;es adotaram condutas &#224; luz de sua experi&#234;ncia e convic&#231;&#227;o pessoal. Por vezes, inclusive, meramente convic&#231;&#227;o pol&#237;tica, numa demonstra&#231;&#227;o de desrespeito ao paciente transformado em cabo eleitoral durante a pandemia. Nesse contexto, para eximir-se de sua responsabilidade regulat&#243;ria, <italic>alguns</italic> Conselhos de classe, com honrosas exce&#231;&#245;es, insistiram em que, dada a urg&#234;ncia, interven&#231;&#245;es sem qualquer comprova&#231;&#227;o de efic&#225;cia fossem aceitas caso houvesse consenso entre o m&#233;dico e o paciente. Curiosamente, acreditavam estar protegendo o m&#233;dico com tal atitude. Mas se o consenso subjuga a regulamenta&#231;&#227;o, e se n&#227;o for poss&#237;vel impor ci&#234;ncia a impress&#245;es pessoais, para que Conselho? Em vez de insistir em promover o debate e a ado&#231;&#227;o de condutas baseadas em evid&#234;ncia cient&#237;fica, optaram pela estrat&#233;gia de &#8220;se n&#227;o fizer mal, pode&#8221;.</p>
    <sec>
      <title>Jabuticaba</title>
      <p>O Brasil tem um ambiente m&#233;dico peculiar. Interven&#231;&#245;es tais como hidroxicloroquina, ivermectina desapareceram completamente do debate cient&#237;fico no resto do mundo. Essas e outras condutas n&#227;o comprovadas, continuam a ser usadas apenas em ensaios cl&#237;nicos. Em parte, gra&#231;as a importantes contribui&#231;&#245;es brasileiras recentemente publicadas. Apesar de v&#225;rios pa&#237;ses terem aceito o resultado desses estudos brasileiros, conduzidos com todo o rigor que a gravidade da pandemia e o m&#233;todo cientifico exigem, muitos no Brasil insistem em question&#225;-los. Tal como a jabuticaba - natural e predominante, mas n&#227;o exclusivamente nossa -, a discuss&#227;o continua atual s&#243; no Brasil. Antes se dizia que os estudos feitos em outros pa&#237;ses n&#227;o se aplicavam &#224; popula&#231;&#227;o brasileira. Agora, continuam a procurar o subgrupo do subgrupo onde a interven&#231;&#227;o possa ser justificada e a partir dali extrapolar os eventuais resultados para toda a popula&#231;&#227;o mesmo sem qualquer comprova&#231;&#227;o cient&#237;fica. Como indiv&#237;duo, entendo que seja dif&#237;cil aceitar evid&#234;ncia em contr&#225;rio &#224; convic&#231;&#227;o de algu&#233;m, mas como m&#233;dico, essa atitude torna-se obrigat&#243;ria.</p>
      <p>Nesse ambiente de completa desregulamenta&#231;&#227;o, v&#225;rios colegas optaram por subscrever abaixo-assinado, criar sites promovendo condutas pessoais, escrever cartas a pol&#237;ticos e at&#233; organizar caravanas &#224; Bras&#237;lia para pressionar o Estado brasileiro a adotar condutas m&#233;dicas por eles defendidas mesmo em face a evid&#234;ncia cient&#237;fica em contr&#225;rio, ou seja, evid&#234;ncia da inefic&#225;cia da interven&#231;&#227;o. Embora muitos deles sejam excelentes m&#233;dicos em suas respectivas &#225;reas de atua&#231;&#227;o, esse tipo de atitude s&#243; foi poss&#237;vel porque, com a desculpa de tentar ajudar, tudo se permite no Brasil. Houvesse algum tipo de norma propondo multa ou cassa&#231;&#227;o da licen&#231;a m&#233;dica aos que promovessem condutas m&#233;dicas n&#227;o comprovadas, nada disso teria acontecido. Tal regulamenta&#231;&#227;o seria, na verdade, semelhante a conduta dos conselhos &#233;ticos em casos de charlatanismo, quando atos m&#233;dicos baseados em decis&#245;es consensuais n&#227;o s&#227;o aceitos como justificativa para isentar o infrator. Mas esse tipo de responsabiliza&#231;&#227;o e presta&#231;&#227;o de conta por condutas tomadas &#233; muito falho ou inexistente no Brasil. Existe um termo em l&#237;ngua inglesa pr&#243;prio para descrever essa imputabilidade chamada de <italic>&#8220;accountability&#8221;</italic>. Curiosamente, essa palavra n&#227;o existe em portugu&#234;s. Pra compensar, jabuticaba n&#227;o tem tradu&#231;&#227;o.</p>
      <p>Este tipo de ato pol&#237;tico, disfar&#231;ado de ato m&#233;dico, congrega alguns pontos em comum. Primeiro, tenta criar um ambiente de inseguran&#231;a junto a popula&#231;&#227;o e imprensa, sugerindo de maneira irrespons&#225;vel que existe um conluio entre ind&#250;stria farmac&#234;utica, principais revistas m&#233;dicas do mundo e pesquisadores para aprovar estrat&#233;gias de alto custo e excluir popula&#231;&#245;es menos privilegiadas. Essa desconfian&#231;a, frequente em momentos de crise, tornou-se quase certeza, quando dois trabalhos n&#227;o-randomizados foram retirados de duas das mais importantes revistas m&#233;dicas internacionais da atualidade. Mas ao contr&#225;rio do que se apregoava, o sistema de avalia&#231;&#227;o da produ&#231;&#227;o cient&#237;fica mostrou-se muito eficaz, cr&#237;tico e resolutivo com essa a&#231;&#227;o r&#225;pida. Em apenas duas semanas, atento ao questionamento de outros m&#233;dicos e investigadores, os trabalhos foram retirados pelos autores, a empresa que forneceu os dados desapareceu e o principal autor da publica&#231;&#227;o foi duramente repreendido pela escola m&#233;dica onde trabalha. N&#227;o porque tenha agido premeditadamente com m&#225;-f&#233;, mas porque n&#227;o observou regras b&#225;sicas de metodologia cient&#237;fica. O controle de qualidade funcionou desse lado da balan&#231;a.</p>
      <p>Mas os que se posicionam contra o m&#233;todo cientifico, atitude que tenta justificar a imobilidade e incapacidade de se organizar, continuam ilesos. Para o desalento deles, todavia, apenas a dexametasona foi confirmada como interven&#231;&#227;o eficaz at&#233; o momento: uma droga barata, gen&#233;rica e com licen&#231;a para ser produzida em qualquer pa&#237;s do mundo sem pagamento de <italic>royalty</italic>. Mais uma vez, o compl&#244; n&#227;o pode ser demonstrado.</p>
      <p>Geralmente formado por pessoas sem nenhum interesse ou experi&#234;ncia em publica&#231;&#227;o cient&#237;fica, que encontram na resist&#234;ncia ao m&#233;todo uma maneira singular de colocarem-se em evid&#234;ncia sem nunca terem produzido nada, o grupo dos &#8220;descrentes&#8221; despendeu uma enorme energia nesse atual movimento anti-ci&#234;ncia no Brasil tentando convencer a todos sobre seus m&#233;todos e opini&#245;es. Silenciosamente rejeitados pela maioria dos m&#233;dicos, esses grupos continuam a buscar apoio fora do ambiente acad&#234;mico, segundo eles, irremediavelmente corrompido. Ao inv&#233;s disso, como fizeram outros, deveriam ter se organizado para responder a perguntas relevantes e beneficiar a popula&#231;&#227;o mundial como um todo. Mas isso d&#225; trabalho: &#233; sempre mais f&#225;cil resistir, reclamar e protestar do que produzir algo novo.</p>
    </sec>
    <sec>
      <title>Trabalhos Brasileiros</title>
      <p>A pergunta mais importante no momento &#233;: qual conjunto de tr&#234;s palavras tem feito mais v&#237;timas? &#8220;Na minha experi&#234;ncia&#8221; ou &#8220;ensaio cl&#237;nico randomizado&#8221;? A experi&#234;ncia, muitas vezes definida como a pr&#243;pria arte da medicina em si, &#233; fundamental n&#227;o para a interpreta&#231;&#227;o dos dados de um estudo, mas para ajudar a acomodar aqueles resultados a um paciente e condi&#231;&#227;o cl&#237;nica espec&#237;fica. O estudo randomizado seleciona e afunila a an&#225;lise sobre um grupo de pacientes para permitir a obten&#231;&#227;o de resultados objetivos. A experi&#234;ncia permite a extrapola&#231;&#227;o e adapta&#231;&#227;o de resultados comprovados, mas n&#227;o deve ser utilizada para interpretar resultados de pesquisa cient&#237;fica. Existem regras para isso e as diferen&#231;as de interpreta&#231;&#227;o s&#227;o tamb&#233;m baseadas nessas normas e n&#227;o em impress&#245;es pessoais.</p>
      <p>Em contraponto aos grupos que defendem a experi&#234;ncia in&#233;dita e a mem&#243;ria recente como estrat&#233;gias para a defini&#231;&#227;o de condutas m&#233;dicas, &#233; preciso destacar o feito extraordin&#225;rio de um grupo de pesquisadores brasileiros. Foram v&#225;rios trabalhos publicados em revistas m&#233;dicas important&#237;ssimas no intervalo de algumas semanas. A iniciativa desses autores tem sido elogiada no mundo inteiro. Nenhum pa&#237;s conseguiu se organizar de maneira t&#227;o eficiente para responder quest&#245;es relevantes &#224; pandemia como o Brasil.</p>
      <p>S&#243; existe uma forma de aprendermos a tratar uma doen&#231;a: pesquisa cl&#237;nica. &#201; um desafio tremendo. Uma pesquisa cl&#237;nica bem-feita deve ser ampla, com muitos pacientes e cen&#225;rios diferentes; &#225;gil e coordenada, para resolver os problemas rapidamente e permitir avan&#231;os terap&#234;uticos; e randomizada, com grupo controle para conseguir isolar o efeito do tratamento.<sup><xref ref-type="bibr" rid="B3">3</xref></sup> Pouqu&#237;ssimos pa&#237;ses conseguiram coordenar movimentos dessa magnitude, que n&#227;o s&#243; decifram a Covid-19 como nos fornecem respostas sobre o que fazer. O Brasil foi um deles. O grupo Coaliz&#227;o, formado por hospitais l&#237;deres no pa&#237;s e que envolve mais de 50 centros nacionais, &#233; hoje refer&#234;ncia mundial. Ser&#227;o cerca de 11 estudos para sanar d&#250;vidas de como tratar a Covid-19. Gra&#231;as ao Brasil, qualquer m&#233;dico que queira tratar pacientes com Covid-19 aprendeu que a hidroxicloroquina, com ou sem azitromicina, n&#227;o teve benef&#237;cio em casos leves a moderados de Covid-19 (Coaliz&#227;o I),<sup><xref ref-type="bibr" rid="B4">4</xref></sup> e que a azitromicina tamb&#233;m n&#227;o teve benef&#237;cio em casos graves (Coaliz&#227;o II).<sup><xref ref-type="bibr" rid="B5">5</xref></sup> Al&#233;m de nos ensinar o que n&#227;o funciona, o grupo ratificou que a Covid-19 grave tem tratamento: a dexametasona beneficiou pacientes hospitalizados com s&#237;ndrome da ang&#250;stia respirat&#243;ria aguda (SARA) moderada-grave, acelerando a sa&#237;da da ventila&#231;&#227;o mec&#226;nica (Coaliz&#227;o III).<sup><xref ref-type="bibr" rid="B6">6</xref></sup> Al&#233;m dos estudos Coaliz&#227;o, pesquisadores brazucas produziram estudos epidemiol&#243;gicos de qualidade indiscut&#237;vel, desenvolveram ensaios cl&#237;nicos em condi&#231;&#245;es prec&#225;rias, sanaram a d&#250;vida global sobre o que fazer com o paciente Covid-19 em uso de iECA ou BRA<sup><xref ref-type="bibr" rid="B7">7</xref></sup> &#8211; sim, ele pode seguir com sua medica&#231;&#227;o &#8211;, e est&#227;o testando e produzindo vacinas com potencial de ajudar milh&#245;es de pessoas. Nos pr&#243;ximos 6 meses, s&#227;o esperados novos estudos avaliando o efeito da hidroxicloroquina fora do ambiente hospitalar (tomara que funcione nesses pacientes como profil&#225;tico), de diferentes anticoagulantes e do poss&#237;vel efeito antiviral do tociluzumabe dentre outros. Um feito incr&#237;vel e sem precedentes no Brasil.</p>
      <p>A pandemia mostrou o que h&#225; de melhor e pior na medicina brasileira. A politiza&#231;&#227;o de um conjunto de condutas m&#233;dicas por m&#233;dicos &#233; inaceit&#225;vel pois exp&#245;e a popula&#231;&#227;o aos riscos de tal conduta, criando fact&#243;ides e cren&#231;as. Ap&#243;s o t&#233;rmino da pandemia, os acertos parecer&#227;o naturais, &#243;bvios e que sempre estiveram ali a nossa disposi&#231;&#227;o. O esfor&#231;o e a metodologia para a obten&#231;&#227;o de tais respostas parecer&#227;o demasiados. As cren&#231;as e os achismos ficar&#227;o.</p>
      <p>A ingest&#227;o de alho em casos de gripe &#233; provavelmente uma das heran&#231;as da Peste Negra quando se acreditava que a transmiss&#227;o da doen&#231;a ocorria pelo mau odor &#8211; flegma &#8211; e o alho, que quando esmagado libera alicina, outras ess&#234;ncias e perfumes poderiam prevenir a doen&#231;a. S&#233;culos depois, a cren&#231;a popular ainda persiste: quem nunca tomou alho para tratar uma gripe?<sup><xref ref-type="bibr" rid="B8">8</xref></sup> In&#250;meros trabalhos sugerem que o alho tenha de fato efeito antiviral. Apesar de estudos randomizados nunca terem demonstrado tal ben&#233;fico de maneira contundente, o mito continua porque afinal de contas: 1) n&#227;o custa nada tentar; mal n&#227;o deve fazer; 2) se n&#227;o cura pelo menos n&#227;o atrapalha; 3) teve um amigo meu que tomou e ficou bom e 4) parece que funciona em outras doen&#231;as e 5) s&#243; estou tentando ajudar. Mais ou menos o mesmo n&#237;vel de evid&#234;ncia que tem sido usado para justificar algumas interven&#231;&#245;es na COIVD-19. Portanto, muitos podem legitimamente preferir tomar ivermectina e zinco em caso de gripe forte. Afinal, se havia uma suspeita, mesmo que infundada, de que funcionasse para a Covid-19, por que n&#227;o funcionaria em uma gripe comum. Essa &#233; uma das eventuais consequ&#234;ncias nocivas de tais condutas instintivas n&#227;o baseadas em estudos adequados.</p>
      <p>E quem ser&#225; responsabilizado por isso? Nessa hora, o movimento anti-ci&#234;ncia se divide entre os &#8220;convertidos&#8221;, os que desaparecem para mais tarde se mobilizar em torno de temas igualmente pol&#234;micos e repetir a estrat&#233;gia, e os que se organizam para tirar proveito financeiro da situa&#231;&#227;o, continuando a prescrever e incentivando tais condutas. As consequ&#234;ncias negativas para a sa&#250;de da popula&#231;&#227;o s&#227;o incalcul&#225;veis. Portanto, n&#227;o parece justo que apenas a resist&#234;ncia sem sentido tenha voz nesse momento. A popula&#231;&#227;o pode e deve confiar na ci&#234;ncia m&#233;dica brasileira quando compreendida e exercida de maneira adequada. Houve um enorme amadurecimento da pesquisa cl&#237;nica no Brasil por conta da pandemia. Muitos outros bons frutos vir&#227;o a partir daqui. Ficou evidente nossa capacidade de aceitar e resolver desafios dessa magnitude. E quem sabe n&#227;o est&#225; no extrato da jabuticaba a melhora da Covid-19!? Mas o que &#233; realmente importante &#233; a mensagem deixada pelos m&#233;dicos e pesquisadores brasileiros &#224;s novas gera&#231;&#245;es: acreditem! Porque no final, o rigor e o treino do astronauta sempre prevalecem.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Agradecimentos</title>
      <p>Os autores gostariam de agradecer a Sra. Elayne Crestani Pereira Msc,PhD (<italic>dissertare.com.br</italic>), ao Sr. J&#250;lio Tude d&#8217;Avila e ao Dr. Andr&#233; Zimerman pelas sugest&#245;es e revis&#227;o cr&#237;tica desse manuscrito.</p>
    </ack>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. Barreto-Filho JAS, Veiga A, Correia LC. COVID-19 and Uncertainty: Lessons from the Frontline for Promoting Shared Decision Making. Arq Bras Cardiol. 2020 28;115(2):149-51.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barreto</surname>
              <given-names>JAS</given-names>
              <suffix>Filho</suffix>
            </name>
            <name>
              <surname>Veiga</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Correia</surname>
              <given-names>LC</given-names>
            </name>
          </person-group>
          <article-title>COVID-19 and Uncertainty: Lessons from the Frontline for Promoting Shared Decision Making</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2020</year>
          <day>28</day>
          <volume>115</volume>
          <issue>2</issue>
          <fpage>149</fpage>
          <lpage>151</lpage>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. d&#8217;Avila A, Melo MFV, Lopes RD. Pandemonium During the Pandemic: What is the Role of Health and Science Professionals? Arq Bras Cardiol. 2020 1;114(5):753-4.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>d&#8217;Avila</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Melo</surname>
              <given-names>MFV</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>Pandemonium During the Pandemic: What is the Role of Health and Science Professionals?</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2020</year>
          <day>1</day>
          <volume>114</volume>
          <issue>5</issue>
          <fpage>753</fpage>
          <lpage>754</lpage>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3. Fernandes JL. Covid-19 in Brazil: Learning How to Walk in the Dark Without Leaving Anything Behind. Arq Bras Cardiol. 2020;114(6):988-91.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandes</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Covid-19 in Brazil: Learning How to Walk in the Dark Without Leaving Anything Behind</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2020</year>
          <volume>114</volume>
          <issue>6</issue>
          <fpage>988</fpage>
          <lpage>991</lpage>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LC, Veiga VC, Avezum A. Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020 Nov 19;383(21):2041-52.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cavalcanti</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Zampieri</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Rosa</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Veiga</surname>
              <given-names>VC</given-names>
            </name>
            <name>
              <surname>Avezum</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19</article-title>
          <source>N Engl J Med</source>
          <year>2020</year>
          <month>11</month>
          <day>19</day>
          <volume>383</volume>
          <issue>21</issue>
          <fpage>2041</fpage>
          <lpage>2052</lpage>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. Furtado RH, Berwanger O, Fonseca HA, C&#244;rrea TD, Ferraz LR, Lapa MG. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. COALITION COVID-19 Brazil II Investigators. Lancet. 2020:3;396(10256):959-67.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furtado</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Berwanger</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Fonseca</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>C&#244;rrea</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Ferraz</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Lapa</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. COALITION COVID-19 Brazil II Investigators</article-title>
          <source>Lancet</source>
          <year>2020</year>
          <day>3</day>
          <volume>396</volume>
          <issue>10256</issue>
          <fpage>959</fpage>
          <lpage>967</lpage>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. COALITION COVID-19 Brazil III Investigators. JAMA. 2020 Sep 2;324(13):1307-16.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomazini</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Maia</surname>
              <given-names>IS</given-names>
            </name>
            <name>
              <surname>Cavalcanti</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Berwanger</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Rosa</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Veiga</surname>
              <given-names>VC</given-names>
            </name>
          </person-group>
          <article-title>Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. COALITION COVID-19 Brazil III Investigators</article-title>
          <source>JAMA</source>
          <year>2020</year>
          <month>09</month>
          <day>2</day>
          <volume>324</volume>
          <issue>13</issue>
          <fpage>1307</fpage>
          <lpage>1316</lpage>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7. Lopes RD, Macedo AV, Silva PG, Moll-Bernardes RJ, Feldman A, D&#8217;Andr&#233;a SA. BRACE CORONA investigators. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) -The BRACE CORONA Trial. Am Heart J . 2020 Aug;226:49-59.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopes</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Macedo</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Moll-Bernardes</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>D&#8217;Andr&#233;a</surname>
              <given-names>SA</given-names>
            </name>
            <collab>BRACE CORONA investigators</collab>
          </person-group>
          <article-title>Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) -The BRACE CORONA Trial</article-title>
          <source>Am Heart J</source>
          <year>2020</year>
          <month>08</month>
          <volume>226</volume>
          <fpage>49</fpage>
          <lpage>59</lpage>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>8. Lissiman E, Bhasale AL, Cohen M. Garlic for the common cold. Cochrane Database Syst Rev. 2014 Nov 11;2014(11):CD006206.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lissiman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bhasale</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Garlic for the common cold</article-title>
          <source>Cochrane Database Syst Rev</source>
          <year>2014</year>
          <month>11</month>
          <day>11</day>
          <volume>2014</volume>
          <issue>11</issue>
          <size units="pages">CD006206</size>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The Astronaut and the Jabuticaba</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-8769-1411</contrib-id>
          <name>
            <surname>d&#8217;Avila</surname>
            <given-names>Andre</given-names>
          </name>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Melo</surname>
            <given-names>Marco F. Vidal</given-names>
          </name>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1001">
        <label>1</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Hospital SOS Cardio, Florian&#243;polis, SC - Brazil</institution>
      </aff>
      <aff id="aff2001">
        <label>2</label>
        <country country="US">USA</country>
        <institution content-type="original">Harvard Medical School - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts &#8211; USA</institution>
      </aff>
      <author-notes>
        <corresp id="c01001"><bold>Mailing Address: Andre d&#8217;Avila &#8226;</bold> Hospital SOS Cardio - 401.121. Postal Code 88030-000, Florian&#243;polis, SC &#8211; Brazil E-mail: andredavila@mac.com </corresp>
      </author-notes>
      <kwd-group xml:lang="en">
        <kwd>Pandemics/prevention and control</kwd>
        <kwd>Dexamethasone</kwd>
        <kwd>Anti-Inflamatory</kwd>
        <kwd>Hydroxychloroquine</kwd>
        <kwd>COVID-19</kwd>
        <kwd>SARS-CoV-2</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>Every two years, of the thousands of applications from all over the world, only 100 are considered eligible to undergo medical, physical and psychological examinations at NASA for astronaut training. Similar to what happens in medical schools, the selection process to identify which candidates are qualified to fly on space missions is extremely competitive. Only 0.1% of applicants are accepted. Comparable to what happens with medical students, some of the candidates cancel their application once they become aware of the rigorous workload and risks of becoming an astronaut. Aspiring physicians and astronauts have similar traits &#8211; they need to be motivated, laser focused on tasks at hand, able to complete exhaustive training, and appreciate the possible catastrophic consequences associated with misconduct.</p>
      <p>Physicians, like astronauts, are frequently perceived as exceptional individuals who are capable of making pragmatic and prompt decisions based on the best available information. Medical decision making, like a shuttle launch, requires thorough preparation rather than blind faith that with keeping one&#8217;s fingers crossed everything will be ok. Patients look to a physician who can make informed decisions coupling evidence-based medicine, guidelines and professional experience. However, variations in clinical practice are common. While it is easy to separate the extremes of excellent care from flagrant malpractice it remains a large gap between these two boundaries, where medical decisions are often made and adequate quality control is difficult.</p>
      <p>This lack of oversight in &#8220;grey&#8221;<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup> zones has become clear during the COVID-19 pandemic. From rectal ozone therapy &#8211; funny, if it were not tragic &#8211; to studies showing the inefficacy of several therapies, many physicians and institutions have made therapeutic decisions based on anecdotal experience or personal belief and, not rarely, on political conviction. In this context, to exempt themselves from their regulatory responsibilities, <italic>some</italic> medical councils, with honorable exceptions, have advocated that interventions without proven efficacy could be accepted if consensus between the doctor and the patient exists. However, if unanimity subjugates legislation, and if science cannot prevail over personal impressions, what is the value of such councils? Instead of promoting fruitful debates and adoption of evidence-based practice, a strategy of &#8220;if it is not bad, why not?&#8221; became acceptable.</p>
      <sec>
        <title>Jabuticaba</title>
        <p>Brazil has a peculiar medical environment. Although interventions like hydroxychloroquine and ivermectin disappeared from the international scientific debate once disproved in clinical trials, Brazilian practitioners continue to debate the validity of these studies. Like <italic>jabuticaba</italic> &#8211; a fruit native to and predominant (but not exclusive) in Brazil &#8211; this debate is still current only in this country. Previous attempts to discount the results of studies with the argument that they had been conducted abroad and could not be extended to the Brazilian population can no longer be justified as many of these studies have included Brazilian patients. As individuals, we do understand the difficulty in accepting evidence opposing someone&#8217;s conviction; however, as a doctor, this attitude is indefensible.</p>
        <p>In this context of conviction and belief over evidence and data, several practitioners have created websites and even solicited the government to support and disseminate their practice despite proven inefficacy of the proposed interventions. Even though many are excellent physicians in their fields, this situation has only been possible because, under the auspices of trying to help, almost anything has been allowed in Brazil. If there were any regulation proposing a fine or termination of medical license to those who supported unproven medical practices, none of this would have happened. This regulation would be, in fact, similar to previous decisions of ethics committees in cases of charlatanism, when medical practices based on consensual decisions are not accepted as justification to exempt the infringer. However, these types of regulations are defective or absent in Brazil. Curiously, the term &#8220;accountability&#8221;, that in English means an obligation or willingness to accept responsibility for one&#8217;s actions, does not exist in Portuguese. On the other hand, there is no English word for &#8220;<italic>jabuticaba</italic>&#8221;.</p>
        <p>Those promoting unproven medical practices are likely unknowingly participating in the political non-sense debate surrounding the COVID-19 pandemic. Their engagement creates an unsafe atmosphere around both population and the press, as they irresponsibly suggest an alliance between the pharmaceutical industry, important medical scientific journals, and researchers to approve high-cost strategies and exclude less privileged populations. This conspiracy theory, common in situations of crisis, became almost a certainty when two non-randomized trials were published in two of the most important international medical journals today. But the scientific peer-review process was shown to be very effective, critical and resolute in response to the concerns from other independent physicians and researchers. In only two weeks, the studies were retracted by the authors and the company that had provided the data disappeared. Furthermore, the main authors were sharply rebuked by the medical schools where they work, because in an effort to help, they disregarded the basic principles of scientific methodology. This is to be contrasted with the fact that Brazilian physicians who have stood against science suffer no consequence. These groups have spent enormous energy on the anti- science movement in Brazil, trying to convince the general population about their opinions. Silently rejected by most physicians, the anti-science movement has gained traction outside the academic realm, the latter which they deem as irretrievably corrupted. Instead, they should have positioned themselves to help answering important questions to benefit the whole population. However this is a lot of work! It is always easier to resist, complain and protest than to produce something scientifically relevant.</p>
      </sec>
      <sec>
        <title>Brazilian Studies</title>
        <p>Which three words have created more victims, &#8220;in my opinion&#8221; or &#8220;randomized clinical trials&#8221;? Although experience, or the &#8220;art of medicine&#8221;, is valuable, it should complement the interpretation of scientific data and help apply results of scientific studies to specific patients and clinical situations. This contrasts with the belief that the &#8220;art of medicine&#8221; is simply a tool to promote one&#8217;s anecdotal experience and recent memory of medical practice as strategies to establish standards of care. This approach devalues the extraordinary work of Brazilian researchers, who in a few weeks published several papers in renowned medical journals receiving global recognition. Their work set Brazil apart from other nations who have not been able to scientifically answer as many important questions about the COVID-19 pandemic as the Brazilian medical community.</p>
        <p>The only way to advance medical practice is through well done clinical investigation. Few countries have been able to coordinate the processes necessary to perform well done, impeccable investigation to answer the challenges of COVID-19. Brazil is one of the countries that was up to it. Today, the <italic>Coalition</italic> group, consisting of leading hospitals and more than 50 national centers, is a global reference. Nearly 11 studies have been conducted on COVID-19 treatment.<sup><xref ref-type="bibr" rid="B3">3</xref></sup> Thanks to Brazil, physicians have learned that hydroxychloroquine with or without azithromycin did not improve clinical status of patients with mild-to-moderate COVID-19 (COALITION I),<sup><xref ref-type="bibr" rid="B4">4</xref></sup> and that azithromycin is not effective in severe COVID-19 also (COALITION II).<sup><xref ref-type="bibr" rid="B5">5</xref></sup> In addition to teaching us what not to do, the group has also confirmed that severe COVID-19 can be treated: hospitalized patients with moderate or severe acute respiratory distress syndrome (ARDS) due to COVID-19 benefited from intravenous dexamethasone, increasing the number of ventilator-free days (COALITION III).<sup><xref ref-type="bibr" rid="B6">6</xref></sup> Besides the COALITION studies, Brazilian researchers have produced high-quality epidemiological work, developed clinical trials in precarious conditions, answered the global question of how to treat COVID-19 patients receiving angiotensin-converting enzyme inhibitors and angiotensin receptor blockers<sup><xref ref-type="bibr" rid="B7">7</xref></sup> &#8211; yes, these therapies may be continued &#8211; and have been testing and producing vaccines that will potentially help millions of people. In the next six months, new studies will evaluate the efficacy of hydroxychloroquine in the out-of-hospital setting (hopefully it has a prophylactic effect), the role of different anticoagulants and the antiviral effect of tociluzumab. This is an astonishing and unprecedented achievement for Brazil.</p>
        <p>The COVID-19 pandemic has revealed the best and worst of Brazilian medicine. The unscientific approach to medicine is unacceptable, places the population at risk, creates fake-news, and overshadows excellence in scientific endeavors within our country. After the pandemic, our success will seem natural, obvious, and inevitable; the efforts and methods to obtain all the answers will seem excessive; but dogmas will remain.</p>
        <p>The use of garlic to treat patients with influenza is likely a remnant of the Black Death, when it was believed that transmission of the disease occurred through bad odors &#8211; phlegm -, and garlic and other essences could prevent the disease. Centuries later, this popular belief persists. Who has never eaten garlic to treat a flu?<sup><xref ref-type="bibr" rid="B8">8</xref></sup> Numerous studies have suggested that garlic has an antiviral effect. Although there are no randomized studies showing these effects, the myth still exists, since: 1) &#8220;it is probably not bad, so why not?&#8221;; 2) &#8220;it may not cure you, but it could help you&#8221;; 3) &#8220;a friend of mine used it and got better&#8221;; 4) &#8220;it seems to work in other diseases&#8221;; 5) &#8220;I am just trying to help&#8221;. These are almost the same level of evidence on which some interventions in COVID-19 have been based. In the future, many patients could genuinely prefer to take ivermectin or zinc in case of severe influenza, since &#8220;if it could be effective for COVID-19, why would it not be effective for a common flu?&#8221; The trickle-down effect of unvalidated practices is not trivial.</p>
        <p>The anti-science movement is currently divided among 3 groups: 1) the &#8220;converted&#8221; ones, 2) those who will be off the scene and show up again using the same strategy when another pandemic issue arises, and 3) those who take financial advantage of the situation by prescribing these drugs of unknown efficacy and encouraging these practices. Consequences to population health can be disastrous. Thus, it does not seem fair that only those who refuse to place their trust in the scientific method have a say today. Clinical research in Brazil has evolved greatly during the pandemic: it has become clear that the scientific community within our country has the capacity to overcome colossal challenges. The population may and should trust Brazilian medical science when properly understood and applied. And who knows, perhaps the key element to treat COVID-19 will be found in the <italic>jabuticaba</italic> extract?! What really matters is the message to the new generation of Brazilian doctors and researchers: just like for astronauts, rigor and training always prevail in the end.</p>
      </sec>
    </body>
    <back>
      <ack>
        <title>Acknowledgements</title>
        <p>The authors thank Julio d&#8217;Avila and Drs. Andre Zimmerman and Sheldon Singh for their suggestions and critical review of the manuscript.</p>
      </ack>
    </back>
  </sub-article>
</article>
